News
In Silico in Innovation – again!
The European Innovation Council (EIC) has released its second wave of “start-up champions” to receive funding for innovations through the EIC Accelerator. The EIC Accelerator is an initiative to fund and invest in start-ups and small companies to both develop and up scale innovations.
Avicenna Alliance meets with MEPs to discuss in silico medicine
On 7 October, Dr. Liesbet Geris (Research Professor in Biomechanics and Computational Tissue Engineering at the Universities of Liège & Leuven (Belgium) and executive director of the Virtual Physiological Human Institute), on behalf of the Avicenna Alliance, gave a brief informational presentation to MEPs about computer modelling and simulation (CM&S).
The Joint Research Centre advocates for a “paradigm change” to in silico research methods!
For the second week in a row, the Joint Research Centre (JRC) – part of the European Commission’s EU Science Hub – has published an article about in silico medicine, this time calling for a paradigm change to in vitro and in silico research methods.
The European Commission Joint Research Centre publishes a public knowledge base of non-animal models used in immuno-oncology
The Joint Research Centre (JRC), which is part of the European Commission’s EU Science Hub, has published a systematic review of immuno-oncology publications using advanced non-animal models. The JRC has also published an accompanying free, publicly available database of the models they studied.
The State of the (European) Union
On 15 September, Commission President Ursula von der Leyen delivered her second State of the Union speech at the European Parliament in Strasbourg. She took stock of the achievements of the past year and looked ahead in terms of upcoming priorities and challenges, bringing up a variety of relevant issues within three main realms.
The BECA Beat
The European Parliament’s Special Committee on Beating Cancer (BECA) met for the first time in September of 2020. BECA was established to create actionable recommendations for Member States and the EU to strengthen their collective response against cancer. Now, a year later, they have released their draft report "Strengthening Europe in the fight against cancer – towards a comprehensive and coordinated strategy,” written by BECA Rapporteur Véronique Trillet-Lenoir (Renew, FR). This significant milestone introduces the questions, what is next for BECA, and what role will the Avicenna Alliance play? Up until this point, the BECA report has been of key interest to the Alliance because it is one of the main items on the EU’s health agenda during the current trio of presidencies, and thus is an entry point to ensure in silico medicine is part of the EU’s health future.
